Estrogen can be taken by mouth, absorbed through the skin, injected into muscle or fat, dissolved under the tongue, or implanted as a slow-release pellet beneath the skin. Each route delivers the same hormone but differs in how quickly levels rise, how steady they stay, and what side effects are most likely. Choosing among them depends on your goals, your medical history, and how much day-to-day management you want to deal with.
Oral and Sublingual Estradiol
Swallowing an estradiol tablet is the most common starting point for both menopausal hormone therapy and gender-affirming care. The pill is convenient, widely available, and inexpensive. Its main drawback is biological: when you swallow estradiol, it passes through the liver before reaching the rest of your body. That first pass stimulates the liver to produce extra clotting factors, which raises the risk of blood clots compared with routes that skip the liver entirely.
Placing the same tablet under the tongue (sublingual dosing) changes the picture. The hormone absorbs through the thin tissue under the tongue and enters the bloodstream directly. Studies in cisgender women have found that sublingual dosing produces peak blood levels roughly 13 times higher than swallowing the same tablet, along with a more favorable ratio of the body’s two main estrogen forms. Because it largely bypasses the liver, sublingual estradiol is thought to carry less clot risk than the oral route.1PubMed Central. SUN-LB9 Pharmacokinetics of Sublingual Versus Oral Estradiol in Transgender Women The trade-off is that sublingual levels spike fast and drop quickly, so you may need to dose more frequently to keep levels steady. Some people find letting a tablet dissolve under the tongue two or three times a day inconvenient compared with swallowing one pill at breakfast.
Transdermal Patches and Gels
Patches and gels deliver estradiol through the skin, bypassing the liver just as sublingual dosing does. A patch is typically worn on the lower abdomen or buttocks and changed once or twice a week, while a gel is applied daily to the inner arm, thigh, or abdomen.
Blood levels behave somewhat differently between the two. Research comparing patches, gels, and oral tablets found that the gel and the tablet produced a similar degree of fluctuation between peak and trough levels (roughly 55–67%), while the patch showed wider swings of about 89%, with lower levels at the beginning and end of each wearing period.2PubMed. Absorption and bioavailability of oestradiol from a gel, a patch and a tablet In practice, this means some patch users notice a dip in how they feel toward the end of a patch cycle. Gels tend to deliver more consistent day-to-day levels but require you to avoid touching the application site until it dries and to be mindful about skin-to-skin contact with others, since the hormone can transfer.
The biggest advantage of the transdermal route is safety: it carries a substantially lower risk of blood clots and appears friendlier to blood pressure than oral estrogen, as discussed later. For anyone with clotting risk factors, transdermal estradiol is typically the preferred choice.
Injections
Injectable estradiol, usually as estradiol valerate or estradiol cypionate, is injected into muscle or subcutaneous fat on a schedule that ranges from weekly to every two weeks. Injections produce a distinct hormonal pattern: levels climb sharply in the first day or two after the shot, then gradually fall until the next dose. Some people describe this as an emotional or physical roller coaster, especially on longer injection intervals.
A large study of injectable estradiol use across the United States found that the specific type of ester (valerate versus cypionate) and the injection site (intramuscular versus subcutaneous) did not significantly affect the estradiol concentrations achieved.3PubMed Central. Injectable Estradiol Use in Transgender and Gender-Diverse Individuals throughout the United States What matters more is the dose and the interval between shots. Some clinicians now suspect that the dose ranges traditionally recommended in guidelines are higher than necessary and may push levels well above the target range for much of the cycle.4PubMed. The Use of Injectable Estradiol in Transgender and Gender Diverse Adults: A Scoping Review of Dose and Serum Estradiol Levels This is one reason periodic blood monitoring matters, especially in the first year of treatment.
Subcutaneous Pellets
Pellet implants are small crystalline rods of compressed estradiol inserted under the skin, usually in the hip or lower abdomen, through a minor office procedure. The pellet dissolves slowly into surrounding tissue, providing a steady trickle of hormone without any daily action on your part. A single 25 mg pellet can maintain estradiol levels in the range of 50–70 pg/mL for about three months, with levels declining gradually over the following months but staying above baseline for up to six months. When two 25 mg pellets are placed together, mean levels in one trial sat around 113 pg/mL for the first week and remained stable for 24 weeks.5PubMed Central. Subcutaneous Estradiol Pellets as Hormone Therapy in Menopause: Clinical Pharmacology, Patient Selection and Safety Considerations
The convenience is obvious, but pellets come with a catch: once inserted, they cannot easily be removed. An audit of over a hundred postmenopausal women receiving 50 mg pellets found that the median time between implants was about 224 days, and the estimated median time for levels to return to baseline was 311 days, though some women’s levels remained elevated for over three years.6PubMed. Clinical audit of estradiol implant therapy: Long duration of action and implications in non-hysterectomised women That prolonged action means patient selection is important. If you react poorly to a given dose, you may be stuck with it for months.
Dosing Targets and How They Differ by Purpose
The dose you need depends on why you are taking estrogen. For menopausal symptom relief, the guiding principle is to use the lowest effective dose and reassess regularly as circumstances change.7PubMed Central. Menopausal Hormone Therapy-Risks, Benefits and Emerging Options: A Narrative Review In practice, this might mean a 0.5 mg oral estradiol tablet or a low-dose patch. Many menopausal women find symptom relief at blood levels well below 100 pg/mL, so there is no need to push higher.
Gender-affirming feminizing therapy generally aims for higher target levels. The Endocrine Society recommends maintaining serum estradiol in the range of 100–200 pg/mL, which corresponds to the typical premenopausal female range.8PubMed Central. Follow-Up Estradiol Levels Based on Regimen Formulation With Guideline-Concordant Gender-Affirming Hormone Therapy A systematic review confirmed this same 100–200 pg/mL target as the consensus across multiple guidelines for transgender women on oral, subcutaneous, or transdermal estradiol.9PubMed. Estradiol Concentrations for Adequate Gender-Affirming Feminizing Therapy: A Systematic Review Reaching and maintaining that range requires tailoring the dose to the individual, which is why blood work every few months during the first year is standard practice.
What to Expect for Your Skin and Hair
Estrogen affects nearly every layer of the skin. It increases collagen content and quality, thickens the skin, and enhances blood flow to the surface.10PubMed. Hormone replacement therapy and the skin For menopausal women, these changes can reverse some of the dryness, thinning, and wrinkling that accelerate after estrogen levels drop. For transgender women starting feminizing therapy, skin often becomes noticeably softer within the first few months.
Hair responds too, though the timeline is slower. Estrogen extends the growth phase of hair follicles and influences both the hair itself and the oil glands attached to follicles.11PubMed Central. Effect of estrogens on skin aging and the potential role of SERMs After menopause, when estrogen declines relative to androgens, some women experience thinning scalp hair and increased facial hair growth. Estrogen supplementation can improve these patterns, though it will not fully reverse established androgenetic hair loss.12Gynäkologische Endokrinologie. Die Menopause und ihre Auswirkungen auf Haut und Haare In gender-affirming care, body hair typically becomes finer and grows more slowly over one to two years, while scalp hair may thicken modestly. Expectations should be realistic: estrogen will not erase years of terminal hair growth, and many trans women still pursue laser hair removal for facial hair.
Mood and Cognitive Effects
Estrogen is not just a reproductive hormone. It acts on the brain’s serotonin system, influencing mood regulation through multiple pathways. It helps upregulate certain serotonin receptors and reduces the activity of an enzyme that breaks serotonin down, which together create a modest antidepressant-like effect.13PubMed Central. Effects of Hormone Therapy on Cognition and Mood Many people starting estrogen report improved emotional stability, reduced irritability, and a general sense of well-being within the first weeks to months. For menopausal women, relief from mood disturbances is one of the most valued benefits of therapy.
These effects are real but variable. Some people notice little mood change, while others describe it as transformative. The route of delivery may matter here too: the peaks and valleys of injectable estrogen can amplify emotional swings for some users, while the steadier levels from patches or pellets may feel smoother. If you are finding that your mood dips predictably before your next injection, that is worth discussing with your prescriber, since shortening the interval or switching routes can help.
Blood Clot Risk Varies Dramatically by Route
Venous thromboembolism, the medical term for dangerous blood clots in veins, is the risk that gets the most attention in estrogen therapy. But the size of that risk depends enormously on how you take the hormone. The ESTHER study, a landmark case-control study in postmenopausal women, found that oral estrogen users had about four times the odds of a clot compared with non-users, while transdermal estrogen users showed no increased risk at all.14PubMed. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study
A separate large cohort study comparing transdermal patch users to oral estrogen-only users confirmed this pattern, finding that clot rates were significantly lower in the patch group even after accounting for other risk factors.15PubMed. Estradiol transdermal system versus oral estrogen-only hormone therapy More recent reviews focusing on transgender women have reached the same conclusion: modern 17β-estradiol regimens carry substantially lower clot rates than older formulations (especially the now-outdated ethinyl estradiol), and transdermal delivery shows the most favorable safety profile overall.16PubMed Central. Venous Thromboembolism Risk in Transgender Women on Feminizing Hormone Therapy: A Narrative Review of Formulation-Specific Risks, Management Strategies, and Evidence Gaps
The reason comes back to the liver. Oral estrogen’s first pass through the liver stimulates production of clotting factors and inflammatory proteins. Routes that bypass the liver avoid this stimulation. If you smoke, are over 40, have a family history of clotting disorders, or carry other risk factors, transdermal or sublingual delivery deserves strong consideration.
Blood Pressure and Arterial Stiffness
The route of estrogen also matters for cardiovascular markers beyond clotting. A community-based study of postmenopausal women found that those who had ever used oral estrogen had higher systolic and diastolic blood pressure readings compared not only with non-oral users (patches and vaginal formulations) but also with women who had never used hormone therapy at all.17PubMed Central. The Association Between Route of Post-menopausal Estrogen Administration and Blood Pressure and Arterial Stiffness in Community-Dwelling Women Transdermal users had readings comparable to controls. A small randomized trial in Korean postmenopausal women with mild hypertension found that active hormone therapy (both estrogen alone and estrogen-plus-progestogen) reduced arterial stiffness from baseline over 12 weeks.18PubMed Central. Effects of menopausal hormone therapy on ambulatory blood pressure and arterial stiffness in postmenopausal Korean women with grade 1 hypertension
The pattern that keeps emerging across different studies is consistent: non-oral routes look safer for the cardiovascular system. This does not mean oral estrogen is dangerous for every user, but it does mean that your individual risk profile should guide the conversation about which route to choose.
Why Progesterone Often Comes Along for the Ride
If you have a uterus and take estrogen, you almost certainly need to also take a progestogen. Estrogen stimulates the uterine lining to grow, and without periodic or continuous progesterone exposure to counterbalance that growth, the risk of endometrial hyperplasia and eventually endometrial cancer rises. This applies to menopausal women with intact uteruses and, in some clinical protocols, to transgender women as well.
Not all progestogens are created equal. Synthetic progestins reliably protect the endometrium but have a mixed record when it comes to metabolic and cardiovascular effects. Micronized progesterone, which is chemically identical to the progesterone your body produces naturally, allows for more physiological effects and appears to carry a better safety profile across clotting, cardiovascular, and breast cancer outcomes.19PubMed Central. Estradiol and Micronized Progesterone: A Narrative Review About Their Use as Hormone Replacement Therapy The combination of estradiol and oral micronized progesterone has been considered an optimal long-term regimen since at least the 1990s, when a large comparative trial established its advantages.20PubMed. Micronized progesterone: clinical indications and comparison with current treatments If your prescriber offers you a synthetic progestin and you are concerned about side effects, asking about micronized progesterone is a reasonable conversation to have.
Estrogen Monotherapy for Testosterone Suppression
In gender-affirming care, estrogen is often paired with an anti-androgen like spironolactone to suppress testosterone. But there is growing interest in whether estrogen alone, at sufficient doses, can do the job on its own. A small prospective study found that all seven transfeminine patients achieved full testosterone suppression when their estradiol levels exceeded 100 pg/mL, with most of those patients using injectable formulations.21Journal of the Endocrine Society. 7472 Estrogen Monotherapy for Testosterone Suppression in Gender Diverse Patients A larger study reinforced this finding, reporting that injectable estradiol monotherapy suppressed testosterone in about 83% of patients, which was comparable to combination therapy with anti-androgens or progestogens.22PubMed. Injectable Estradiol Monotherapy Effectively Suppresses Testosterone in Gender-Affirming Hormone Therapy
This matters because anti-androgens come with their own side effects. Spironolactone can cause dizziness, frequent urination, and electrolyte imbalances. If injectable estradiol at an adequate dose can suppress testosterone by itself, dropping the anti-androgen simplifies the regimen and removes those side effects. Not everyone responds to monotherapy, though, and transdermal routes appear less reliable at achieving full suppression than injections. This is a decision to make with lab work in hand, not based on assumptions about your dose.
Bone Density
Estrogen is one of the primary hormones that keeps bones strong. When estrogen levels drop, whether from menopause, surgical removal of the ovaries, or testosterone suppression without adequate estrogen replacement, bone density declines. A meta-analysis of studies on transdermal estrogen in postmenopausal women found that lumbar spine bone density increased by about 3.4% after one year and 3.7% after two years of treatment compared with baseline values.23PubMed Central. The Effects of Transdermal Estrogen Delivery on Bone Mineral Density in Postmenopausal Women: A Meta-analysis Those numbers may sound modest, but they represent the difference between stable bone and progressive loss, which compounds year over year.
For transgender women, bone health is an underappreciated concern. Anti-androgen therapy suppresses testosterone (which also contributes to bone density) before estrogen has had time to fully compensate. If estrogen levels are kept in the target range, bone density is generally maintained. But if levels run low, perhaps because of inconsistent dosing or a route that is not delivering enough hormone, bone loss can happen silently. A DEXA scan at baseline and periodically during treatment can catch problems early.
Why the Same Dose Affects People Differently
One of the most frustrating things about estrogen therapy is the variability. Two people on the same dose, same route, and same schedule can end up with very different blood levels and very different experiences. Genetics are a major reason. Variations in the genes that encode estrogen-metabolizing enzymes and estrogen receptors can change how quickly your body processes the hormone and how strongly your tissues respond to it.24PubMed. Genetic variation of estrogen metabolism and the risks of cardiovascular disease These polymorphisms may also influence susceptibility to side effects like clotting and mood changes.25PubMed. Genetic variability in estrogen disposition: Potential clinical implications for neuropsychiatric disorders
Body composition, liver function, other medications, and even how well your skin absorbs a patch or gel all add layers of variability. This is why titrating estrogen is more of an iterative process than a one-and-done prescription. Your prescriber picks a reasonable starting dose based on your weight, age, and goals, then adjusts based on blood work and how you feel. Expecting the first dose to be the right dose sets you up for disappointment. Most people go through at least one adjustment in the first six months.
What Happens When You Stop
Whether you are discontinuing estrogen after menopause because you feel ready, or stopping temporarily for a medical procedure, withdrawal is rarely seamless. A study of over 800 women who attempted to stop hormone therapy found that three-quarters experienced hot flashes after discontinuation. Trouble sleeping and mood disturbances were particularly common among those who tried to stop but ultimately resumed. Women who had sleep disruptions were significantly less likely to succeed in quitting, as were those who experienced mood swings or depression.26PubMed Central. Factors Associated with Successful Discontinuation of Hormone Therapy
Factors that predicted successful discontinuation included having a doctor advise stopping, learning coping strategies for symptoms, and, perhaps surprisingly, not having seen symptom improvement on the therapy in the first place (people who were not getting much benefit found it easier to let go). Gradual tapering rather than abrupt cessation is the approach most clinicians recommend, though the evidence on whether tapering actually reduces rebound symptoms is thinner than you might expect. If you are planning to stop, having a conversation with your prescriber about a stepdown schedule and non-hormonal options for managing any returning symptoms is the practical move.
For transgender women, the calculus around stopping is different. Discontinuing estrogen without resuming testosterone (either endogenous or exogenous) leaves the body without a dominant sex hormone, which accelerates bone loss and can worsen mood, energy, and metabolic health. If estrogen must be paused for surgical reasons, the interruption is typically kept as short as possible, and bone-protective strategies may be discussed for longer gaps.